Literature DB >> 22105465

Interferon free hepatitis C treatment regimens: the beginning of another era.

Fred Poordad1, Grace M Chee.   

Abstract

Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22105465     DOI： 10.1007/s11894-011-0229-1

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  17 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

3.  Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Authors:  P Glue; J W Fang; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

4.  Boceprevir for untreated chronic HCV genotype 1 infection.

Authors:  Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

5.  Telaprevir for retreatment of HCV infection.

Authors:  Stefan Zeuzem; Pietro Andreone; Stanislas Pol; Eric Lawitz; Moises Diago; Stuart Roberts; Roberto Focaccia; Zobair Younossi; Graham R Foster; Andrzej Horban; Peter Ferenci; Frederik Nevens; Beat Müllhaupt; Paul Pockros; Ruben Terg; Daniel Shouval; Bart van Hoek; Ola Weiland; Rolf Van Heeswijk; Sandra De Meyer; Don Luo; Griet Boogaerts; Ramon Polo; Gaston Picchio; Maria Beumont
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

6.  Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors:  Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2011-06-23       Impact factor: 91.245

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

9.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245
View more
  4 in total

1.  The future developments in hepatology: no need for a jaundiced view.

Authors:  Ahmed Mohamed Elsharkawy; Mark Hudson
Journal:  Frontline Gastroenterol       Date:  2012-05-31

2.  Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes.

Authors:  M Michele Manos; Chanda K Ho; Rosemary C Murphy; Valentina A Shvachko
Journal:  Patient       Date:  2013       Impact factor: 3.883

3.  In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.

Authors:  Christian Voitenleitner; Renae Crosby; Jill Walker; Katja Remlinger; Jessica Vamathevan; Amy Wang; Shihyun You; John Johnson; Ermias Woldu; Stephanie Van Horn; Joseph Horton; Katrina Creech; J Brad Shotwell; Zhi Hong; Robert Hamatake
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

4.  Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.

Authors:  Stefania Paolucci; Loretta Fiorina; Bianca Mariani; Roberto Gulminetti; Stefano Novati; Giorgio Barbarini; Raffaele Bruno; Fausto Baldanti
Journal:  Virol J       Date:  2013-12-17       Impact factor: 4.099
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.